Group 1 - The core viewpoint of the article highlights the performance and market position of Huatai Medical, which closed at 432.84 yuan with a PE ratio of 62.39 times, significantly higher than the industry average of 43.49 times [1][2] - Huatai Medical's total market capitalization is reported at 42.021 billion yuan, ranking 101st in the industry based on PE ratio [1][2] - The company specializes in the research, production, and sales of cardiovascular interventional medical devices, with its electrophysiological electrode catheters being the first domestically approved products, establishing it as a leading manufacturer in the domestic electrophysiology market [1] Group 2 - For the third quarter of 2024, Huatai Medical reported a revenue of 1.525 billion yuan, reflecting a year-on-year increase of 25.63%, and a net profit of 528 million yuan, up 30.97% year-on-year, with a gross profit margin of 72.69% [1] - As of the latest report, only one institution holds shares in Huatai Medical, with a total of 6000 shares valued at 0.02 million yuan [1]

Core Viewpoint - Shenzhen Huatai Medical Devices Co., Ltd. will participate in the 2024 annual performance briefing for the medical device industry on April 25, 2025, to discuss its operational results, financial status, cash dividend plan, and development strategy with investors [2][3][4]. Group 1: Event Details - The performance briefing is scheduled for April 25, 2025, from 15:00 to 17:00 [4]. - The event will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [4][5]. - Investors can submit questions via email or phone by April 24, 2025, to have their inquiries addressed during the briefing [5]. Group 2: Participants - Key participants include Chairman Ge Hao, Vice General Manager and Financial Officer Dai Zhenhua, and Independent Director Xia Lijun [4]. Group 3: Accounting Policy Change - The company announced a change in accounting policies in accordance with the Ministry of Finance's new guidelines, effective January 1, 2024, which will not affect previously disclosed financial statements or the company's financial status [9][10][11]. - The changes include the implementation of new accounting standards regarding the classification of current and non-current liabilities, supplier financing arrangements, and accounting for sale-leaseback transactions [10][11].

重要内容提示： 会议召开时间：2025年4月25日(星期五)15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于2025年4月24日(星期四)16:00前通过邮件、电话等形式将需要了 解和关注的问题提前提供给公司。公司将在说明会上对投资者普遍关注的问题进 行回答。 证券代码：688617 证券简称：惠泰医疗 公告编号：2025-012 深圳惠泰医疗器械股份有限公司 关于参加 2024 年度科创板医疗器械行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 董事、副总经理、财务负责人兼董事会秘书：戴振华先生 深圳惠泰医疗器械股份有限公司（以下简称"公司"）将于2025年4月23日 发布公司2024年年度报告，为便于广大投资者更全面深入地了解公司2024年度经 营成果、财务状况、现金分红方案、发展战略等情况，公司计划于2025年4 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-011 2024 年 12 月 6 日，财政部发布了《企业会计准则解释第 18 号》（财会〔2024〕 24 号）（以下简称"准则解释 18 号"），规定了"关于不属于单项履约义务的保 证类质量保证的会计处理"，对不属于单项履约义务的保证类质量保证产生的预 计负债，应当按确定的金额计入"主营业务成本"和"其他业务成本"等科目， 不再计入"销售费用"科目。该解释规定自印发之日起施行，允许企业自发布年 度提前执行。公司自 2024 年 1 月 1 日起执行。 二、本次会计政策变更的主要内容 本次会计政策变更前，公司执行财政部《企业会计准则——基本准则》以及 各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他相 关规定。 深圳惠泰医疗器械股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计政策变更系深圳惠泰医疗器械股份有限公司（以下简称"公司"） 根据中华人民共和国财政部（以下简称"财政部" ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown mixed performance, with a recent decline of 1.18% and a year-to-date drop of 3.06% [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,112.97 points with a trading volume of 12.648 billion [1]. - Over the past month, the index has decreased by 8.47%, while it has increased by 1.50% over the last three months [1]. - The index was established on December 31, 2004, with a base point of 1,000.0 [1]. Group 2: Index Composition - The top ten weighted companies in the index include Mindray Medical (9.22%), Aier Eye Hospital (8.37%), and United Imaging Healthcare (7.65%) [1]. - The index is composed entirely of companies from the healthcare sector, with a market share distribution of 60.07% from the Shenzhen Stock Exchange and 39.93% from the Shanghai Stock Exchange [1][2]. Group 3: Fund Tracking - Several public funds track the index, including Southern CSI Healthcare Equipment and Services Link A, Tianhong CSI Healthcare Equipment and Services ETF, and others [2].

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent increase but a decline over the past month and year-to-date [1] Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 0.32% to 13,285.51 points, with a trading volume of 13.924 billion yuan [1] - Over the past month, the index has decreased by 8.06%, while it has increased by 4.05% over the last three months and has declined by 3.25% year-to-date [1] Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1] - The top ten weighted companies in the index include Mindray Medical (9.16%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.43%) [1] - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.27%) and the Shanghai Stock Exchange (39.73%) [1] Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the second Friday of June and December [2] - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management [2]

Company Overview - Shenzhen Huatai Medical Devices Co., Ltd. specializes in the research, production, and sales of cardiovascular interventional medical devices, with key products including electrophysiology, coronary access, peripheral vascular interventional, and non-vascular interventional medical devices [1] - The company's electrophysiological electrode catheters and radiofrequency ablation electrode catheters are the first domestically approved products, establishing a leading position in the domestic electrophysiology market [1] Financial Performance - For the third quarter of 2024, the company reported a revenue of 1.525 billion yuan, representing a year-on-year increase of 25.63% [1] - The net profit for the same period was 528 million yuan, showing a year-on-year growth of 30.97% [1] - The gross profit margin stood at 72.69% [1] Market Position - As of the latest report, Huatai Medical's stock closed at 433.0 yuan, with a PE ratio of 62.42, marking a new low in 125 days [1] - The total market capitalization of the company is 42.036 billion yuan [1] - In comparison to the industry average PE ratio of 46.15 and the median of 29.13, Huatai Medical ranks 100th in the industry [2] Institutional Holdings - A total of 479 institutions hold shares in Huatai Medical, with 478 being funds and 1 being a brokerage, collectively holding 30.0891 million shares valued at 11.203 billion yuan [1]

Group 1 - The core viewpoint of the news is that the CSI Medical Index has shown fluctuations, with a recent increase of 1.73% despite a decline of 11.00% over the past month [1] - The CSI Medical Index reflects the overall performance of listed companies in the medical and healthcare sector, including medical devices, services, and information technology [1] - The index has a base date of December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the CSI Medical Index include WuXi AppTec (9.9%), Mindray Medical (9.27%), and Aier Eye Hospital (8.27%) [1] - The market share of the CSI Medical Index holdings is 57.98% from the Shenzhen Stock Exchange and 42.02% from the Shanghai Stock Exchange [1] - The industry composition of the CSI Medical Index holdings shows that 97.49% is in healthcare, 2.25% in information technology, and 0.26% in consumer goods [1] Group 3 - The index sample is adjusted every six months, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to specific calculation and maintenance guidelines [2]

交易信息汇总 截至2025年4月3日收盘，惠泰医疗(688617)报收于414.9元，上涨0.22%，换手率0.5%，成交量4868.0手，成交额2.01亿元。 当日关注点 资金流向方面，惠泰医疗在2025年4月3日的交易中，主力资金净流出442.92万元，占总成交额2.2%；游资资金净流入525.11万元，占总成交额 2.61%；散户资金净流出82.19万元，占总成交额0.41%。 公司公告汇总 深圳惠泰医疗器械股份有限公司发布了关于部分高级管理人员减持股份计划的公告。副总经理韩永贵持有公司股份124,364股，占公司总股本 0.1281%，计划通过集中竞价、大宗交易方式减持合计不超过30,000股，不超过公司总股本的0.0309%。集中竞价交易减持期间为自公告披露之日 起15个交易日后的三个月内，任意连续90个自然日内减持的股份总数不超过公司总股本的1%；大宗交易减持期间同样为自公告披露之日起15个交 易日后的三个月内，任意连续90个自然日内减持的股份总数不超过公司总股本的2%。减持原因为自身资金需求。韩永贵在股份锁定承诺中表示， 自发行上市之日起12个月内不转让或委托他人管理所持股份，在担任公司董事、监 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688617 证券简称：惠泰医疗 公告编号：2025-010 深圳惠泰医疗器械股份有限公司 部分高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上述减持主体无一致行动人 董监高最近一次减持情况 ● 董监高持股的基本情况 截至本公告披露日，深圳惠泰医疗器械股份有限公司（以下简称"公司"）副总经理韩永贵先生（以下简 称"减持主体"）持有公司股份124,364股，占公司目前总股本0.1281%。 ● 减持计划的主要内容 公司于近日收到公司副总经理韩永贵先生的《关于股份减持计划的告知函》，减持主体拟通过集中竞 价、大宗交易方式减持，合计不超过30,000股，即不超过公司总股本的0.0309%。通过集中竞价交易的 方式减持的，在任意连续90个自然日内减持的股份总数不超过公司总股本的1%，减持期间为自本公告 披露之日起15个交易日后的三个月内；通过大宗交易的方式减持的，在任意连续90个自然日内减持的股 份总数不超过公司总 ...